BR112012027915A2 - nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo - Google Patents

nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo

Info

Publication number
BR112012027915A2
BR112012027915A2 BR112012027915A BR112012027915A BR112012027915A2 BR 112012027915 A2 BR112012027915 A2 BR 112012027915A2 BR 112012027915 A BR112012027915 A BR 112012027915A BR 112012027915 A BR112012027915 A BR 112012027915A BR 112012027915 A2 BR112012027915 A2 BR 112012027915A2
Authority
BR
Brazil
Prior art keywords
fatty acids
cognitive decline
neuroprotection
inhibition
nitro fatty
Prior art date
Application number
BR112012027915A
Other languages
English (en)
Inventor
Miller Raymond
Original Assignee
Nitromega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitromega Corp filed Critical Nitromega Corp
Publication of BR112012027915A2 publication Critical patent/BR112012027915A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

nitro-ácidos graxos-neuroproteção e/ou inibição do declínio cognitivo. uma composição para tratar, melhorar e/ou prevenir condições associadas com o declínio cognitivo e/ou morte neurono-motora compreende um componente ácido graxo enriquecido a um ou mais ácidos graxos ativados e um excipiente nutraceuticamente aceitável. um método para tratar, melhorar e/ou prevenir condições associadas com o declínio cognitivo e/ou morte neurono-motora inclui a administração de um componente ácido graxo-enriquecido a um ou mais ácidos graxos ativados.
BR112012027915A 2010-05-13 2011-05-13 nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo BR112012027915A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33448410P 2010-05-13 2010-05-13
PCT/US2011/036481 WO2011143587A1 (en) 2010-05-13 2011-05-13 Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline

Publications (1)

Publication Number Publication Date
BR112012027915A2 true BR112012027915A2 (pt) 2018-10-23

Family

ID=44911975

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012027915A BR112012027915A2 (pt) 2010-05-13 2011-05-13 nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo

Country Status (6)

Country Link
US (2) US8563609B2 (pt)
EP (1) EP2568826A4 (pt)
JP (1) JP2013526865A (pt)
CN (1) CN102843922B (pt)
BR (1) BR112012027915A2 (pt)
WO (1) WO2011143587A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2180787T3 (da) 2007-08-01 2014-02-03 Univ Pittsburgh Nitrooliesyremodulering af type ii-diabetes
CN102083787A (zh) 2008-05-01 2011-06-01 康普雷克萨公司 乙烯基取代的脂肪酸
EP2299997A4 (en) 2008-06-19 2012-01-11 Univ Utah Res Found USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2011014261A1 (en) 2009-07-31 2011-02-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fatty acids as anti-inflammatory agents
CA2781276A1 (en) 2009-10-02 2011-04-07 Complexa, Inc. Heteroatom containing substituted fatty acids
BR112012027915A2 (pt) * 2010-05-13 2018-10-23 Nitromega Corp nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo
US20110319325A1 (en) * 2010-06-28 2011-12-29 Complexa, Inc. Multi-component pharmaceuticals for treating diabetes
EP2726086A4 (en) * 2011-06-30 2015-04-29 Nitromega Corp COMPOSITIONS CONTAINING FATTY NITROACIDS
EP2744491B1 (en) 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
JP5991836B2 (ja) * 2012-03-28 2016-09-14 小林製薬株式会社 ギンコライドと魚介油を含有する組成物
US20150246061A1 (en) * 2012-10-19 2015-09-03 Celus Pharmaceuticals, Inc. Vitamin d analogues for the treatment of a neurological disorder
US9637731B2 (en) 2013-03-05 2017-05-02 Innovative Environmental Technologies, Inc. Heavy metal stabilization and methane inhibition during induced or naturally occurring reducing conditions in contaminated media
US9221699B2 (en) * 2013-03-05 2015-12-29 Innovative Environment Technologies, Inc. Inhibition of methane production during anaerobic reductive dechlorination
WO2014180827A1 (en) * 2013-05-06 2014-11-13 Dsm Ip Assets B. V. Powderous vitamin e formulation
WO2015048554A1 (en) * 2013-09-26 2015-04-02 National University Of Singapore Compositions and methods utilizing lysophosphatidylcholine scaffolds
US20150147305A1 (en) * 2013-11-22 2015-05-28 Houn Simon Hsia Asthmatic and Allergenic Nutritional Composition
US20150157046A1 (en) * 2013-12-10 2015-06-11 Lifewave, Inc. Nutritional product composition for the mind
CN106102765A (zh) 2014-02-07 2016-11-09 犹他大学研究基金会 肌酸、ω‑3脂肪酸和胞磷胆碱的组合
EP2915431A1 (en) * 2014-03-04 2015-09-09 Lifewave, Inc. A nutritional product composition for the mind
GB201405033D0 (en) 2014-03-20 2014-05-07 Isis Innovation Combination therapy
TW201618802A (zh) 2014-07-22 2016-06-01 希格納營養學股份有限公司 用於調控ｐｐ２ａ甲基化反應並提供抗氧化及抗發炎活性之天然萃取物
CN104587087B (zh) 2014-12-30 2018-10-23 神威药业集团有限公司 一种治疗心脑血管疾病的药物组合物
WO2016179137A1 (en) * 2015-05-04 2016-11-10 Cytometix, Inc. Compositions and methods for delivery of polyunsaturated fatty acid derivatives and analogs
DK3303339T3 (da) 2015-07-07 2021-04-12 H Lundbeck As Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
US10610556B2 (en) * 2015-09-17 2020-04-07 Therapeutic Solutions LLC Compositions for regulation and control of appetite
CN113440506A (zh) * 2015-10-02 2021-09-28 康普莱克夏公司 使用治疗有效量的活化脂肪酸预防、治疗和逆转疾病
US20170128401A1 (en) * 2015-11-05 2017-05-11 Jason Daniel Dooney Dietary composition for improved performance
KR101785970B1 (ko) 2015-12-04 2017-10-17 연세대학교 원주산학협력단 올레산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 근육손실 예방 및 치료용 약학적 조성물
CN105767829A (zh) * 2016-04-25 2016-07-20 山东福田药业有限公司 一种改善大脑认知能力的功能饮料及制备方法
WO2017213490A1 (en) * 2016-06-10 2017-12-14 N.V. Nutricia Method for controlling neuroinflammation
WO2018027081A1 (en) * 2016-08-04 2018-02-08 Seattle Gummy Company Health management compositions and methods of making and using thereof
US10765652B2 (en) 2016-10-05 2020-09-08 University of Pittsburgh—of the Commonwealth System of Higher Education Reversible nitroxide derivatives of nitroalkenes that mediate nitrosating and alkylating reactions
CN108079008A (zh) 2016-11-23 2018-05-29 上海泽生科技开发股份有限公司 促进胃肠系统动力的复合维生素组合物
WO2018148821A1 (en) * 2017-02-16 2018-08-23 Neurodyn Life Sciences Inc. Composition and method for improving cognitive function and brain bioavailability of ginseng and ginsenosides and treating neurodegenerative disease and neurological disorders
CN108567792A (zh) * 2017-03-07 2018-09-25 上海泽生科技开发股份有限公司 一种治疗阿尔茨海默病的复合维生素组合物
CN110381935A (zh) * 2017-04-11 2019-10-25 雀巢产品有限公司 用于识别和减轻个体的认知衰老的ω-3脂肪酸和维生素D水平
WO2018188771A1 (en) * 2017-04-11 2018-10-18 Nestec S.A. Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
US11065288B2 (en) 2017-09-29 2021-07-20 Kinjirushi Co., Ltd. Neuron activator
IT201700121764A1 (it) * 2017-10-26 2019-04-26 Neilos S R L Composizione per il trattamento e/o la prevenzione di patologie neurodegenerative.
KR102116046B1 (ko) * 2018-03-22 2020-05-27 뉴트리진 주식회사 오메가3 지방산을 포함하는 인지 장애 질환 예방 또는 치료용 조성물
KR102207952B1 (ko) * 2018-12-28 2021-01-27 주식회사 네이처센스 실크 펩타이드를 포함하는 치매, 뇌졸증 및 인지 기능 개선용 조성물
WO2021242758A1 (en) * 2020-05-26 2021-12-02 Imara Inc. Improved nitro-fatty acid oral dose regimens
CU20210060A7 (es) 2021-07-13 2023-02-13 Centro Nac De Investigaciones Cientificas Mezcla de compuestos con altos pesos moleculares, obtenida a partir de la cera de caña de azúcar (saccharum officinarum l.)
WO2024003385A1 (en) * 2022-07-01 2024-01-04 N.V. Nutricia Nutritional composition for neurodegeneration and neurotrauma
GB202214771D0 (en) * 2022-10-07 2022-11-23 Nicoventures Trading Ltd Oral product

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
WO2000067596A1 (en) * 1999-05-07 2000-11-16 Trustees Of Tufts College Immune stimulating dietary supplement and methods of use thereof
JP2000325040A (ja) * 1999-05-17 2000-11-28 Nonogawa Shoji Kk 学習・記憶能力改善食品
AUPQ291499A0 (en) 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
US6346231B1 (en) 1999-10-06 2002-02-12 Joar Opheim Flavored gelatin capsule and method of manufacture
ES2239155T3 (es) 2000-06-28 2005-09-16 Zambon Group S.P.A. Proceso para la preparacion de nitroalquenos.
US6579866B2 (en) * 2000-12-28 2003-06-17 Mccleary Larry Composition and method for modulating nutrient partitioning
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
WO2005016864A1 (en) 2003-07-29 2005-02-24 The Arizona Disease Control Research Commission Conjugated nitro alkene anticancer agents based on isoprenoid metabolism
WO2005062849A2 (en) * 2003-12-19 2005-07-14 Elixir Pharmaceuticals, Inc. Lifespan management
WO2005110396A2 (en) * 2004-04-28 2005-11-24 Uab Research Foundation Nitrated lipids and methods of making and using thereof
US7645795B2 (en) 2004-09-21 2010-01-12 BodyBio, Inc Method for treating amyotrophic lateral sclerosis
JP2006199666A (ja) * 2005-01-24 2006-08-03 Nagase & Co Ltd 健忘症の予防・治療剤
FR2886154B1 (fr) 2005-05-27 2010-03-26 Cothera Composition pour retarder le developpement de la maladie d'alzheimer
JP2008050331A (ja) * 2006-08-24 2008-03-06 Noriyuki Washino 痴呆症（認知症）に有用な新規摂食組成物
WO2008153426A1 (en) 2007-06-15 2008-12-18 Sealord Group Limited Anti-inflammatory composition and use thereof
DK2180787T3 (da) 2007-08-01 2014-02-03 Univ Pittsburgh Nitrooliesyremodulering af type ii-diabetes
CN103285394B (zh) 2008-04-18 2016-01-20 犹他大学研究基金会 使用硝化脂质治疗脂质病症和肥胖以及与脂质和肥胖相关的病状
CN102083787A (zh) 2008-05-01 2011-06-01 康普雷克萨公司 乙烯基取代的脂肪酸
EP2299997A4 (en) 2008-06-19 2012-01-11 Univ Utah Res Found USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES
WO2010014889A2 (en) 2008-08-01 2010-02-04 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Nitro fatty acids as regiomers and related mimetics
EP2384114A4 (en) 2008-12-31 2013-10-23 Nitromega Corp NUTRACEUTICALS CONTAINING NITROPTANT ACIDS
US20100286257A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
US20100286271A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Nitro-alkyl Compound Compositions
US20100286272A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications
WO2011014261A1 (en) 2009-07-31 2011-02-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fatty acids as anti-inflammatory agents
CA2781276A1 (en) 2009-10-02 2011-04-07 Complexa, Inc. Heteroatom containing substituted fatty acids
US8470879B2 (en) 2009-11-02 2013-06-25 Life Technologies Corporation Fatty acid inhibitors
BR112012027915A2 (pt) * 2010-05-13 2018-10-23 Nitromega Corp nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo
WO2011152832A1 (en) 2010-06-04 2011-12-08 N.V. Perricone Llc Methods of use of nitroalkene compositions in dermatologic applications to prevent or treat skin aging
US20110319325A1 (en) 2010-06-28 2011-12-29 Complexa, Inc. Multi-component pharmaceuticals for treating diabetes

Also Published As

Publication number Publication date
JP2013526865A (ja) 2013-06-27
US8563609B2 (en) 2013-10-22
US20140017219A1 (en) 2014-01-16
US9308189B2 (en) 2016-04-12
EP2568826A4 (en) 2014-03-26
CN102843922B (zh) 2015-12-16
WO2011143587A1 (en) 2011-11-17
EP2568826A1 (en) 2013-03-20
US20110280852A1 (en) 2011-11-17
CN102843922A (zh) 2012-12-26

Similar Documents

Publication Publication Date Title
BR112012027915A2 (pt) nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo
ECSP15002815A (es) Metodos para reducir el riesgo de un evento cardiovascular en un sujeto con terapia con estanina
CU20130137A7 (es) Derivados de ácido 3- fenilpropiónico ramificados y su uso
CO6771409A2 (es) Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
CU24037B1 (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
BR112015003729A8 (pt) Composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
BR112014018879A8 (pt) Composto e composição farmacêutica e combinação compreendendo dito composto
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
BR112012008889A2 (pt) compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes
BR112012021364A2 (pt) "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas".
BR112013017845A2 (pt) agente antidiabético de abaixamento de lipídio
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
CL2015000289A1 (es) Compuesto citostatico derivado de niclosamida y compuesto alquilante derivado de 2,3,4,6,8-pentazabiciclo[4.3.0]nona-2,7-trieno; composicion farmaceutica que los comprende; y metodo para determinar si el tratamiento para un paciente con un tumor solido es adecuado.
BR112013000776A2 (pt) método e formulação para tratamento de deficiência de ácido siálico
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
BR112012005044B8 (pt) composição farmacêutica que compreende uma combinação de (rac)-tramadol·hcl e celecoxib
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112018006445A2 (pt) métodos para tratar distrofia muscular
BR112013001301A2 (pt) processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
BR112014024308A8 (pt) uso de neuregulina para tratar lesão de nervo periférico
BR112012018765A2 (pt) agente profilático ou terapêutico para as doenças do trato biliar
BR112013001462B8 (pt) Composições
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2514 DE 12/03/2019.